CSBIO(SZ:300255)2023-04-21 16:00Production Capacity and Product Development - The company is expanding its heparin raw material production capacity by 35 tons to address capacity bottlenecks and enhance net profit margins from heparin raw materials[7]. - The company is actively promoting the bulk export and international registration of non-pig heparin products[8]. - The company has developed advanced biochemical technologies that significantly improve product yield and reduce production cycles, achieving standards higher than industry norms[2]. - The company plans to expand its raw material drug production capacity and actively promote innovative drug research and development[147]. - The company is actively developing non-pig source low molecular weight heparin, with successful HALAL certification for bovine heparin sodium products in Indonesia and Malaysia[155]. - The company is advancing the clinical trials for Abenatide injection, with all subjects enrolled by January 2022, and is progressing with two anti-tumor targeted new drugs in preclinical research[154]. - The company’s research institute focuses on expanding its heparin product line, polysaccharide and peptide products, and developing anti-tumor drugs, with increased investment in R&D planned for the coming years[172]. Financial Performance - The company achieved operating revenue of CNY 2,336.23 million in 2022, a decrease of 21.29% compared to the previous year[129]. - The net profit attributable to shareholders was CNY 17.51 million, representing a decline of 92.50% year-on-year[147]. - Domestic sales accounted for 72.94% of total revenue, while international sales contributed 27.06%, with international sales decreasing by 37.49%[129]. - The gross profit margin for the biopharmaceutical sector was 45.71%, down 13.44% from the previous year[130]. - Revenue from low molecular weight heparin preparations dropped by 27.55% to $1,205,645,412.90, representing 51.61% of total revenue[187]. - Revenue from ordinary heparin raw materials was $596,724,641.10, accounting for 25.54% of total revenue, down 13.78%[187]. - The revenue from ordinary heparin preparations surged by 196.24% to $35,517,662.19, making up 1.52% of total revenue[187]. - Other revenue sources contributed $63,319,199.97, which is 2.71% of total revenue, down 19.86% year-over-year[187]. Corporate Governance and Internal Control - The company maintains a strong commitment to corporate governance, ensuring compliance with relevant laws and regulations[13]. - The company emphasizes talent development and has established a drug research institute to ensure continuous technological innovation[4]. - The company is optimizing its internal control system to mitigate management risks and enhance operational efficiency[10]. - The independent directors provided impartial opinions on the annual profit distribution plan and external guarantees during the reporting period[35]. - The company has maintained a risk-oriented approach in its internal control supervision activities, with no significant issues reported during the period[37]. - The company has not encountered any significant internal control deficiencies in financial reporting during the reporting period[96]. - The company has a complete mechanism for determining the remuneration of directors and senior management based on performance and capability assessments[63]. Environmental Compliance - The company has completed environmental impact assessments for multiple projects, including a series of polysaccharide and protein peptide products[79]. - The company has obtained pollution discharge permits valid until 2026 for its subsidiaries, ensuring compliance with environmental regulations[81]. - The company has implemented a self-monitoring plan for environmental compliance, with all monitoring results meeting the relevant discharge standards[91]. - The wastewater treatment facility processed a total of 42,410.52 tons of wastewater in 2022, with no instances of exceeding discharge standards[87]. - The company’s air pollution control systems, including a chemical deodorization system and a biological deodorization system, operated normally throughout the year, meeting emission standards[111]. - The company has invested approximately CNY 1 million in environmental governance and protection in 2022[119]. - The company has a compensation limit of CNY 3 million for its environmental pollution liability insurance, effective from July 23, 2022, to July 22, 2023[122]. - The company has not reported any penalties or rectification measures during the reporting period[195]. Market Strategy and Sales - The company has established a mature domestic and international marketing network, reducing dependency on any single market[4]. - The company is adjusting its product and customer structure to adapt to market changes, aiming for higher sales revenue[7]. - The company has a complete and independent production and sales system, allowing for autonomous decision-making and contract signing[50]. - The company has continuously improved its internal control system to adapt to changing external environments and internal management requirements[44]. - The company has established a unique competitive advantage in the industry through 20 years of efforts in supply chain management, quality control, international market layout, and independent innovation, ensuring sustainable growth in performance[168]. Shareholder Communication and Dividends - The company proposed a cash dividend of RMB 0.26 per 10 shares (including tax) based on the total share capital after deducting shares in the repurchase account[40]. - The company has not engaged in any investor communication activities during the reporting period[11]. - The company’s profit distribution plan complies with relevant regulations and the company’s articles of association[41]. - The company has a clear and transparent cash dividend policy that aligns with its articles of association and shareholder resolutions[71]. - The company has not proposed a cash dividend distribution plan despite having positive distributable profits for the parent company during the reporting period[72]. Legal Matters - The company has received four lawsuits related to false securities statements in 2022, with one case still under trial, while two claims were dismissed[185]. - There were no related party transactions involving asset or equity acquisitions or sales during the reporting period[196]. - The company did not engage in any related party debt or equity transactions during the reporting period[198]. - There were no significant contracts that contributed to over 10% of the total profit during the reporting period[190].